Therapeutic targeting of TFE3/IRS-1/PI3K/mTOR axis in translocation renal cell carcinoma.

CONCLUSIONS: These results identify TFE3/IRS-1/PI3K/AKT/mTOR as a potential dysregulated pathway in TFE3-tRCC, and suggest a therapeutic potential of vertical inhibition of this axis by using a dual PI3K/mTOR inhibitor for TFE3-tRCC patients.
PMID: 30061365 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 30, 2018 Category: Cancer & Oncology Authors: Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman EC, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion AR, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst P, Pili R Tags: Clin Cancer Res Source Type: research